Press releases

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.

IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.

First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies. Promising early signals of activity seen as Phase 1 dose escalation proceeds.

Conference Innovation Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology.

IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of immunotherapy.

ImmunoGenesis today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.

ImmunoGenesis and Cancer Focus Fund, LP, announce that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis’ lead candidate, IMGS-001. The investment will support the portion of the IMGS-001 Phase 1a/1b multi-site clinical trial being conducted at MD Anderson. It coincides with ImmunoGenesis’ Series A financing, which is expected to close in the third quarter.

ImmunoGenesis announces that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.

ImmunoGenesis announces that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.

ImmunoGenesis announces that CEO James Barlow will present about the company and its multiple immune-oncology therapeutic development programs at Biotech Showcase 2022 on January 10 at 2:30 PM PST.